Metabolic Associated Fatty Liver Disease
Conditions
Keywords
fatty liver disease
Brief summary
This randomized, controlled, double-blind study evaluates the utility of alpha-lipoic acid and silybum marianum , versus placebo, in the treatment of metabolic associated fatty liver disease.
Detailed description
Between 80-90% of people with associated metabolic fatty liver disease present with obesity and diabetes mellitus. Alpha-lipoic acid is a cofactor of mitochondrial enzymes that has been considered an antioxidant since its reduced form, dihydrolipoate, reacts with reactive oxygen species and thus protects the cell membrane. Alpha-lipoic acid administration has been shown to have beneficial effects on adipokine levels and metabolic disorders such as diabetes and obesity, both of which are present in patients with MAFLD. It has been shown that the administration of 1200 mg of alpha-lipoic acid in patients with fatty liver decreases insulin resistance, serum leptin, increases the concentration of adiponectin. Given the metabolic effects of alpha-lipoic acid, it is hypothesized that administration of this formulation may be beneficial for people with metabolic associated fatty liver disease.
Interventions
DIETARY_SUPPLEMENTLUDLEV®300 mg/46.2 mg
LUDLEV®300 mg/46.2 mg once day
OTHERPlacebo
Placebo treatment (maltodextrin), once daily (u.i.d)
Sponsors
Saluz Investigación S. C.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Intervention model description
Allocation is 1:1 to probiotic and placebo arms
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Subjects treated at the Instituto de Investigaciones Médico Biológicas de la Universidad Veracruzana with a diagnosis of Fatty Liver Disease * Agree to voluntarily participate in the study and sign informed consent. * Patients with evidence of hepatic steatosis who are overweight or obese * Patients with evidence of hepatic steatosis with diabetes mellitus and overweight or obesity. * Patients with evidence of steatosis plus metabolic risk abnormalities will be included (waist circumference \>102 in men, 88 cm in women, blood pressure \>130/85 mmHg or specific treatment, triglycerides \>150 mg/dL or specific treatment, HDL cholesterol \< 40 mg/dL in men, \<50 mg/dL in women or specific treatment, HOMA-IR \>2.5, CRP \>2 mg/L or prediabetes defined by fasting glucose detection 100 to 125 mg/dL, postload glucose 2 hours 140 to 199 mg/dL or HbA1c between 5.7 to 6.4%) * Accept not to start any diet program during the study period. * Agree not to change your current exercise plan during the study period
Exclusion criteria
* Patients meeting diagnostic criteria for Fatty Liver Disease with normal weight * Patients with terminal illness, cancer, renal disease in renal replacement therapy * Pregnant women * Patients with inability to understand or follow the study protocol * Sensitivity to the components of the formula.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transitional elastography with Fibroscan | 30 minutes (performed after a 4-hour fast) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| controlled attenuation parameter (CAP) | 30 minutes (performed after a 4-hour fast) | Hepatic steatosis by controlled attenuation parameter |
| kilopascals (kpa) | 30 minutes (performed after a 4-hour fast) | Hepatic stiffness by Transitional elastography with Fibroscan |
Countries
Mexico
Contacts
Primary ContactANA D CONTRERAS, MD
Outcome results
None listed